SEC Form 4 · accession 0001213900-26-070257
MoonLake Immunotherapeutics · MLTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Spike Loy
Director
Period of report
Jun 17, 2026
Accepted (ET)
Jun 18, 2026 · 6:45 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001821586
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to BuyF1 | $19.19 | Jun 17, 2026 | A | 22,195 | A | — | Jun 17, 2036 | Class A ordinary shares, par value $0.0001 per share | 22,195 | 22,195 | D |
Explanation of responses
- F1This option represents a right to purchase a total of 22,195 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to the Reporting Person's continued service to the Issuer.